Denali Therapeutics (DNLI) Competitors $16.26 -0.70 (-4.10%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, and AXSMShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Abivax Avidity Biosciences Cytokinetics Merus Rhythm Pharmaceuticals CRISPR Therapeutics Grifols Nuvalent Axsome Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Do analysts rate DNLI or BEAM? Denali Therapeutics currently has a consensus target price of $33.50, indicating a potential upside of 105.96%. Beam Therapeutics has a consensus target price of $45.92, indicating a potential upside of 69.36%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.06Beam Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 2.94 Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Denali Therapeutics' return on equity of -40.79% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -40.79% -36.39% Beam Therapeutics -661.31%-43.15%-31.06% Do institutionals & insiders hold more shares of DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor DNLI or BEAM? In the previous week, Denali Therapeutics had 7 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for Denali Therapeutics and 6 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.72 beat Denali Therapeutics' score of 0.52 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, DNLI or BEAM? Denali Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Which has better valuation & earnings, DNLI or BEAM? Beam Therapeutics has higher revenue and earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali TherapeuticsN/AN/A-$422.77M-$2.80-5.81Beam Therapeutics$60.27M45.51-$376.74M-$4.50-6.02 SummaryDenali Therapeutics beats Beam Therapeutics on 9 of the 15 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.40B$3.44B$6.24B$10.56BDividend YieldN/A2.27%5.74%4.88%P/E Ratio-5.8522.9129.0627.16Price / SalesN/A443.52554.75166.44Price / CashN/A46.9837.4561.65Price / Book1.9110.4512.326.45Net Income-$422.77M-$52.55M$3.32B$276.51M7 Day Performance-0.28%-1.35%-1.25%-2.38%1 Month Performance22.11%9.71%5.22%0.49%1 Year Performance-38.13%11.40%61.35%30.73% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.2188 of 5 stars$16.27-4.1%$33.50+106.0%-35.7%$2.40BN/A-5.85430BEAMBeam Therapeutics3.6144 of 5 stars$25.39-3.5%$45.92+80.8%+29.1%$2.66B$63.52M0.00510News CoverageABVXAbivax3.425 of 5 stars$95.63+2.0%$114.25+19.5%+773.0%$7.30BN/A0.0061Short Interest ↓RNAAvidity Biosciences2.6305 of 5 stars$48.96-1.6%$68.32+39.5%+5.0%$7.26B$10.90M-13.75190CYTKCytokinetics3.8753 of 5 stars$59.59-0.7%$76.64+28.6%+7.4%$7.18B$18.47M-11.68250Analyst ForecastInsider TradeMRUSMerus1.4785 of 5 stars$94.85+0.5%$93.12-1.8%+83.3%$7.14B$36.13M-17.2537Short Interest ↓RYTMRhythm Pharmaceuticals3.0346 of 5 stars$100.770.0%$106.64+5.8%+113.5%$6.70B$130.13M-33.48140Insider TradeCRSPCRISPR Therapeutics2.1444 of 5 stars$68.29-6.5%$71.71+5.0%+49.1%$6.65B$37.31M-12.58460Insider TradeGRFSGrifols3.957 of 5 stars$9.45+1.4%$10.30+9.0%+9.0%$6.41B$7.81B8.0823,822Positive NewsNUVLNuvalent2.7294 of 5 stars$89.75+1.9%$118.89+32.5%-3.9%$6.35BN/A-18.3240Analyst RevisionAXSMAxsome Therapeutics4.7456 of 5 stars$121.15-0.5%$177.93+46.9%+43.6%$6.07B$385.69M-23.90380Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Beam Therapeutics Competitors Abivax Competitors Avidity Biosciences Competitors Cytokinetics Competitors Merus Competitors Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Grifols Competitors Nuvalent Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Republican party is falling apartSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeMost traders don’t realize there’s a window of time each day when price movements become highly predictable — ...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts